Abstract
Introduction: Direct anticoagulants (DOAC) have been associated with less calcification and coronary plaque progression in previous trials, since they don’t interfere with vitamin K metabolism. To date, whether different DOACs are associated with differential effects on coronary plaque burden and progression, is not known. We evaluated the 12-month effects of apixaban vs rivaroxaban on atherosclerotic plaque characteristics and vascular morphology in patients with atrial fibrillation, as assessed by quantitative coronary computed tomographic angiography (CCTA).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
